2 %) patients were discontinued prior to month 18 and 2,426 of 3,720 (65.2 %) CBL0137 molecular weight were discontinued prior to month 24; 1,294 of 3,720 patients (34.8 %) completed 24 months of therapy. The primary reasons for discontinuations prior to completing a full course of therapy (i.e., ≥18 months) were the patient’s and physician’s decisions. The mean TPTD exposure (for men and women combined) was 18 months, and the median TPTD exposure was 23 months. Some patients may have received TPTD for more than 24 months, even though the labeling for TPTD limits therapy to 24 months. However, in many cases, duration of SIS3 in vitro greater than 24 months of TPTD

therapy was recorded due to the method of reporting data in this observational study. For example, there may not have been a scheduled visit to collect the date that TPTD was stopped or the next scheduled visit

at which this date was recorded could have occurred after the 24-month calendar time point. The sponsor asked physicians to use Navitoclax research buy TPTD according to product labeling but did not intervene with clinical decision making. Incidence of nonvertebral fragility fractures The incidence of patients experiencing new NVFX during the four TPTD treatment periods was 1.42, 0.91, 0.70, and 0.81 %, respectively (Table 2). The incidence of new NVFX occurring during each of the three TPTD treatment periods was significantly lower than the incidence during the reference treatment period of >0 to ≤6 months (p < 0.05 for all comparisons). Compared to the reference period, the incidence of new NVFX was 36, 51, and 43 % lower when patients were treated for periods of 6 to 12, 12 to 18, and 18 to 24 months, respectively. During the 24-month cessation phase, the incidence of patients experiencing

new NVFX was 0.80, 0.68, 0.33, and 0.33 % during the four periods, respectively. As shown in Table 2 and Fig. 2, the incidence of new NVFX occurring during each of the four cessation periods was significantly lower than the incidence during the reference treatment period of >0 to ≤6 months (p < 0.05 for all comparisons). Table 2 Incidence AMP deaminase of new nonvertebral fragility fractures Duration (months) Number of patients with a new NVFXa Number of patients at risk Incidence (95 % CI)b p valuec Treatment phase >0 to ≤6 53 3,720 1.42 (1.07, 1.86) NA >6 to ≤12 27 2,970 0.91 (0.60, 1.32) 0.0177 >12 to ≤18 18 2,570 0.70 (0.42, 1.10) 0.0019 >18 to ≤24 18 2,225 0.81 (0.48, 1.28) 0.0143 Cessation phase Baselined 53 3,720 1.42 (1.07, 1.86) NA >0 to ≤6 16 2,008 0.80 (0.46, 1.29) 0.0176 >6 to ≤12 12 1,757 0.68 (0.35, 1.19) 0.0087 >12 to ≤18 5 1,536 0.33 (0.11, 0.76) 0.0003 >18 to ≤24 4 1,227 0.33 (0.09, 0.83) 0.